Pharmafile Logo

Enbrel

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Enbrel in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Enbrel.

42

Global Revenue Ranking

Recent articles on PMLiVE featuring Enbrel

- PMLiVE
Novartis sues US government over Medicare drug price negotiation programme

The action comes after the first drugs subject to pricing negotiations were announced

- PMLiVE
US government announces first ten drugs subject to Medicare pricing negotiations

The IRA programme is facing court challenges from leading drugmakers and industry groups

- PMLiVE
Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

- PMLiVE
US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

- PMLiVE
Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Companies will collaborate on novel drugs for autoimmune disorders

- PMLiVE
Cortellis Drugs to Watch in 2020 report

The latest Cortellis Drugs to Watch report highlights medicines that treat high prevalence conditions

- PMLiVE
Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

Celgene building
UPDATED: BMS completes Celgene merger after FTC okay

Approval comes over ten months after acquisition announcement

Novartis building
Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE
Amgen snaps up Celgene’s Otezla for $13.4bn

Higher-than-expected price helps BMS sweeten merger deal

- PMLiVE
Amgen CEO says Aimovig is “one of most successful launches”

Contrasts with cholesterol drug Repatha, its price slahed 60% to lift take-up

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links